International Biotechnology Trust plc - IBT

Investing in biotechnology for a healthier future

Access the fast-growing biotechnology sector through an actively managed, diversified investment trust

Targeting high growth, International Biotechnology Trust plc (IBT) backs innovative companies addressing high unmet medical needs and offers investors the opportunity for financial returns.

Behind the trust - read our philosophy article >

Seeking the best in biotech

International Biotechnology Trust invests in around 100 of the most innovative, high quality quoted and unquoted companies across the entire spectrum of the biotech and other life sciences sectors.

A keen focus on risk management

An acute understanding of valuation and the biotechnology investment cycle informs the managers’ top down overlay and they take prudent steps to reduce individual company risk ahead of binary events. This has contributed to their outperformance against the index and their peers.

Income generating

A dividend of 4% of closing net asset value, paid biannually, offers investors a highly differentiated and reliable source of income.

Portfolio Company Updates

Novartis to acquire Avidity Biosciences - October 2025
Novo Nordisk to acquire Akero - October 2025
Genmab to acquire Merus - September 2025
Pfizer agrees to acquire Metsera - September 2025
Acquisition of 89Bio by Roche - September 2025
Merck to acquire Verona Pharma - July 2025
Sanofi to acquire Blueprint Medicines - June 2025
Merck to acquire SpringWorks - April 2025
Acquisition of Intra-Cellular Therapies by Johnson & Johnson - January 2025

Download Key Material

Annual Report and Accounts 2025
Half Year Report & Accounts 2025
Factsheet
Kepler Research
Key Information Document

Portfolio & Performance Hub

Morningstar-logo-4

Source: Morningstar, October 2025

Logo by the AIC (Association of Investment Companies)

Source: Association of Investment Companies, 2025

citywire aa rating

Source: Citywire, 2025

In the Media

Trustnet: The best funds and trusts in November 2025
Kepler: Results Analysis
Trustnet: Chequebooks at the ready: Biotech is on the shopping list
This is Money: The biotech fund backing companies that could change how we live
Citywire: IBT moved to AA rating for the first time
Citywire: IBT feature on healthcare trust picks
Kepler Market Matters Podcast: IBT's Ailsa Craig
Kepler: Talking Trusts - Interview with Ailsa Craig and Marek Poszepczynski
Investment Week: Biotech innovation will overcome policy noise
Trustnet: The sector-specific trusts consistently outperforming for Sharpe ratio
Kepler: Half Year Results Analysis
Trustnet: Six ISA trust picks for all tastes
James Carthew: Am I too late to switch biotech trust?
Kepler Special Report: Investing in Biotech with Investment Trusts
AIC: IBT named in ISA millionaires list for 2025

Investment Manager's Blog

Documents

Document archive
AGM Results 2024
AIFM Disclosure Statement
Terms of Reference: Management Engagement Committee
Terms of Reference: Nomination Committee
Terms of Reference: Audit Committee
Comparison of Existing and Proposed Articles of Association
Proposed Articles of Association